JP2013517273A - 化合物および方法 - Google Patents

化合物および方法 Download PDF

Info

Publication number
JP2013517273A
JP2013517273A JP2012549000A JP2012549000A JP2013517273A JP 2013517273 A JP2013517273 A JP 2013517273A JP 2012549000 A JP2012549000 A JP 2012549000A JP 2012549000 A JP2012549000 A JP 2012549000A JP 2013517273 A JP2013517273 A JP 2013517273A
Authority
JP
Japan
Prior art keywords
amino
methyl
pyrimidinyl
benzenesulfonamide
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012549000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013517273A5 (OSRAM
Inventor
ララ、エス．カランダー
ブライアン、グリフィン、ローホーン
ジョアンヌ、フィルプ
ツァオ、ヨンドン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of JP2013517273A publication Critical patent/JP2013517273A/ja
Publication of JP2013517273A5 publication Critical patent/JP2013517273A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2012549000A 2010-01-13 2011-01-11 化合物および方法 Pending JP2013517273A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29463710P 2010-01-13 2010-01-13
US61/294,637 2010-01-13
PCT/US2011/020798 WO2011088027A1 (en) 2010-01-13 2011-01-11 Compounds and methods

Publications (2)

Publication Number Publication Date
JP2013517273A true JP2013517273A (ja) 2013-05-16
JP2013517273A5 JP2013517273A5 (OSRAM) 2014-02-20

Family

ID=44304601

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012549000A Pending JP2013517273A (ja) 2010-01-13 2011-01-11 化合物および方法

Country Status (13)

Country Link
US (1) US20120329784A1 (OSRAM)
EP (1) EP2523559A4 (OSRAM)
JP (1) JP2013517273A (OSRAM)
KR (1) KR20120114355A (OSRAM)
CN (1) CN102791131A (OSRAM)
AU (1) AU2011205485B2 (OSRAM)
BR (1) BR112012017277A2 (OSRAM)
CA (1) CA2786999A1 (OSRAM)
EA (1) EA201290642A1 (OSRAM)
IL (1) IL220812A0 (OSRAM)
MX (1) MX2012008141A (OSRAM)
SG (1) SG182351A1 (OSRAM)
WO (1) WO2011088027A1 (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018138522A (ja) * 2017-02-24 2018-09-06 タマ化学工業株式会社 ピリジン−３−スルホニルクロリドの製造方法
JP2020521771A (ja) * 2017-05-26 2020-07-27 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ ベンズイミダゾロン由来のｂｃｌ６阻害剤
US12486285B2 (en) 2018-04-13 2025-12-02 Cancer Research Technology Limited BCL6 inhibitors

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2871375C (en) * 2012-05-03 2020-10-27 F. Hoffmann-La Roche Ag Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease
JP6423372B2 (ja) 2013-02-28 2018-11-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 強力なｒｏｃｋ１およびｒｏｃｋ２阻害剤としてのフェニルピラゾール誘導体
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
EP3935944A1 (en) * 2013-03-15 2022-01-12 University Of Southern California, USC Stevens Compounds for the treatment of musculoskeletal diseases
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
CN104844526B (zh) * 2015-04-16 2018-08-31 温州医科大学 一种4,6-嘧啶二胺类化合物及其制备方法和应用
CN106008366A (zh) * 2016-05-25 2016-10-12 山东大学 一种利匹韦林的制备方法
CN108864052A (zh) * 2018-06-07 2018-11-23 福建医科大学 一种针对gc33-3-1抗体具有特异性识别的荧光探针的合成以及应用
EP4206196A1 (en) * 2021-12-29 2023-07-05 Almirall S.A. Pyrimidine substituted derivatives as tyk2 inhibitors
EP4482825A2 (en) * 2022-02-23 2025-01-01 President and Fellows of Harvard College Inhibitors of ddr1 and ddr2 for the treatment of arthritis
TW202345809A (zh) 2022-03-23 2023-12-01 美商愛德亞生物科學公司 作為parg抑制劑之經哌取代的吲唑化合物
US11891362B1 (en) * 2023-04-14 2024-02-06 King Faisal University N2,N4-disubstituted pyrimidine-2,4-diamine compounds as antibacterial agents
WO2024243304A2 (en) * 2023-05-23 2024-11-28 Quantx Biosciences Us, Inc. Bicyclic heteroaryl compounds
WO2024249831A2 (en) * 2023-06-02 2024-12-05 Unogen Biotech Ltd. Triple kinase inhibitors
US12358904B2 (en) * 2023-06-02 2025-07-15 Atomwise Inc. Inhibitors of TYK2
WO2025096550A1 (en) * 2023-10-31 2025-05-08 Twine Therapeutics, Inc. Methods of treating cardiomyopathy

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000512623A (ja) * 1996-05-10 2000-09-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ドーパミンｄ▲下４▼レセプターアンタゴニストとしての２，４―ジアミノピリミジン誘導体
JP2004535447A (ja) * 2001-06-26 2004-11-25 ブリストル−マイヤーズ　スクイブ　カンパニー ＴＮＦ−α発現のＮ−ヘテロ環インヒビター
WO2005026129A1 (en) * 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
US20070179161A1 (en) * 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
WO2008079907A1 (en) * 2006-12-20 2008-07-03 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2008118822A1 (en) * 2007-03-23 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20080242681A1 (en) * 2004-01-22 2008-10-02 Altana Pharma Ag N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors
WO2008152093A2 (en) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidines as modulators of the ep2 receptor
JP2009513703A (ja) * 2005-11-01 2009-04-02 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
WO2009051822A1 (en) * 2007-10-19 2009-04-23 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
JP2009540013A (ja) * 2006-06-15 2009-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２−アニリノ−４−（複素環）アミノ−ピリミジン

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006129469A (ru) * 2004-01-16 2008-02-27 Новартис АГ (CH) 2, 4-диаминопиримидины и их применение для индукции кардиомиогенеза
UA109411C2 (uk) * 2005-11-01 2015-08-25 N-трет-бутил-3-(2-хлор-5-метилпіримідин-4-іламіно)бензолсульфонамід та його застосування в способі одержання сполуки
CN101589036A (zh) * 2006-12-19 2009-11-25 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的氨基嘧啶

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000512623A (ja) * 1996-05-10 2000-09-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ドーパミンｄ▲下４▼レセプターアンタゴニストとしての２，４―ジアミノピリミジン誘導体
JP2004535447A (ja) * 2001-06-26 2004-11-25 ブリストル−マイヤーズ　スクイブ　カンパニー ＴＮＦ−α発現のＮ−ヘテロ環インヒビター
US20070179161A1 (en) * 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
WO2005026129A1 (en) * 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
US20080242681A1 (en) * 2004-01-22 2008-10-02 Altana Pharma Ag N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors
JP2009513703A (ja) * 2005-11-01 2009-04-02 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
JP2009540013A (ja) * 2006-06-15 2009-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２−アニリノ−４−（複素環）アミノ−ピリミジン
WO2008079907A1 (en) * 2006-12-20 2008-07-03 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2008118822A1 (en) * 2007-03-23 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2008152093A2 (en) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidines as modulators of the ep2 receptor
WO2009051822A1 (en) * 2007-10-19 2009-04-23 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018138522A (ja) * 2017-02-24 2018-09-06 タマ化学工業株式会社 ピリジン−３−スルホニルクロリドの製造方法
JP2020521771A (ja) * 2017-05-26 2020-07-27 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ ベンズイミダゾロン由来のｂｃｌ６阻害剤
JP7202315B2 (ja) 2017-05-26 2023-01-11 キャンサー・リサーチ・テクノロジー・リミテッド ベンズイミダゾロン由来のｂｃｌ６阻害剤
JP2023052069A (ja) * 2017-05-26 2023-04-11 キャンサー・リサーチ・テクノロジー・リミテッド ベンズイミダゾロン由来のｂｃｌ６阻害剤
JP7534379B2 (ja) 2017-05-26 2024-08-14 キャンサー・リサーチ・テクノロジー・リミテッド ベンズイミダゾロン由来のｂｃｌ６阻害剤
US12110286B2 (en) 2017-05-26 2024-10-08 Cancer Research Technology Limited Benzimidazolone derived inhibitors of BCL6
US12486285B2 (en) 2018-04-13 2025-12-02 Cancer Research Technology Limited BCL6 inhibitors

Also Published As

Publication number Publication date
WO2011088027A1 (en) 2011-07-21
US20120329784A1 (en) 2012-12-27
CN102791131A (zh) 2012-11-21
CA2786999A1 (en) 2011-07-21
EP2523559A4 (en) 2013-11-06
IL220812A0 (en) 2012-08-30
MX2012008141A (es) 2012-08-03
EA201290642A1 (ru) 2013-05-30
WO2011088027A8 (en) 2012-08-30
SG182351A1 (en) 2012-08-30
EP2523559A1 (en) 2012-11-21
AU2011205485B2 (en) 2014-09-25
KR20120114355A (ko) 2012-10-16
BR112012017277A2 (pt) 2017-10-03
AU2011205485A1 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
JP2013517273A (ja) 化合物および方法
JP6322205B2 (ja) がん治療用のピリミジン−２，４−ジアミン誘導体
JP4944286B1 (ja) シクロプロパン化合物
KR101962488B1 (ko) 치환된 디아미노카르복스아미드 및 디아미노카르보니트릴 피리미딘, 그의 조성물, 및 그를 사용하는 치료 방법
ES2579830T3 (es) Derivados de diaminopirimidina y procedimientos para la preparación de los mismos
AU2008229147A1 (en) Chemical compounds
TWI434834B (zh) 作為蛋白質激酶抑制劑之吡唑化合物及噻唑化合物、其醫藥組成物及用途
KR20040068317A (ko) 피리미딘 ａ₂ｂ 선택성 길항 화합물, 그의 합성 방법 및용도
CN104884438A (zh) 作为n型钙通道阻滞剂的取代的吡唑
KR20120093428A (ko) 스핑고신 키나아제 저해제
CA3196676A1 (en) Pyrimidine compounds, compositions, and medicinal applications thereof
CA2882127A1 (en) Pyrrolopyrazoles as n-type calcium channel blockers
JP5836963B2 (ja) キナゾリン化合物
CA2933026A1 (en) Novel pyridine pyrazinones as brd4 inhibitors
CN105658644B (zh) 取代咪唑用作n型钙通道阻滞剂
JP2013503170A (ja) 化合物および方法
WO2011088031A1 (en) Compounds and methods
JP2006306861A (ja) ピリミジニルアルキルチオ基を有する新規環式化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131225

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20141113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150508